WO2018237369A3 - Lipid nanoparticle (lnp)-mediated delivery of a crispr-expressing plasmid dna for treating chronic hepatitis b virus infection - Google Patents
Lipid nanoparticle (lnp)-mediated delivery of a crispr-expressing plasmid dna for treating chronic hepatitis b virus infection Download PDFInfo
- Publication number
- WO2018237369A3 WO2018237369A3 PCT/US2018/039179 US2018039179W WO2018237369A3 WO 2018237369 A3 WO2018237369 A3 WO 2018237369A3 US 2018039179 W US2018039179 W US 2018039179W WO 2018237369 A3 WO2018237369 A3 WO 2018237369A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plasmid dna
- crispr
- expressing plasmid
- lnp
- virus infection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided herein is a CRISPR-expressing plasmid DNA and a gene delivery system targeted to hepatocytes infected with hepatitis B virus. Also provided are methods of directing CRISPR system formation in such cells to ensure enhanced specificity for target recognition to alter, improve, or treat chronic HBV infection. In addition the CpG content of the expressing plasmid DNA has been minimized to reduce inflammation and maximize gene expression.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762524389P | 2017-06-23 | 2017-06-23 | |
US62/524,389 | 2017-06-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2018237369A2 WO2018237369A2 (en) | 2018-12-27 |
WO2018237369A3 true WO2018237369A3 (en) | 2019-02-14 |
Family
ID=64735812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/039179 WO2018237369A2 (en) | 2017-06-23 | 2018-06-23 | Lipid nanoparticle (lnp)-mediated delivery of a crispr-expressing plasmid dna for treating chronic hepatitis b virus infection |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018237369A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2595106B (en) * | 2019-01-22 | 2022-10-12 | Emulate Inc | High-content imaging of microfluidic devices |
CA3132164A1 (en) * | 2019-03-06 | 2020-09-10 | Generation Bio Co. | Closed-ended dna (cedna) and immune modulating compounds |
JP7650242B2 (en) | 2019-04-18 | 2025-03-24 | ツールゲン インコーポレイテッド | Composition and method for inhibiting proliferation of hepatitis B virus |
BR112021021979A2 (en) | 2019-05-03 | 2022-12-06 | Specific Biologics Inc | POLYPEPTIDES, CHIMERIC NUCLEASES, PHARMACEUTICALLY ACCEPTABLE FORMULATIONS, METHODS FOR EDITING GENOMIC DNA, DELETING DEFINED LENGTHS OF A DNA MOLECULE AND REPLACING SELECTED SEQUENCES OF A DNA MOLECULE, PROCESS, METHODS OF ADMINISTRATION OF THE FORMULATION, OF TREATMENT OF A DISEASE DISEASE LUNG AND TREATMENT OF MONOGENETIC AND INFECTIOUS DISEASES, LIGAND AND MODIFIED DONOR DNA MOLECULES |
CA3150452A1 (en) * | 2019-09-06 | 2021-03-11 | Generation Bio Co. | Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof |
US20230090515A1 (en) * | 2019-12-20 | 2023-03-23 | Curevac Ag | Lipid nanoparticles for delivery of nucleic acids |
EP4308087A1 (en) * | 2021-03-17 | 2024-01-24 | Board of Regents of the University of Nebraska | Lipid nanoparticle formulations and methods of use thereof |
CN113368261A (en) * | 2021-06-17 | 2021-09-10 | 苏州大学 | Non-viral vector and preparation method and application thereof |
CN114903987A (en) * | 2022-05-31 | 2022-08-16 | 复旦大学 | A kind of mRNA medicine for treating chronic hepatitis B virus infection and its preparation method and application |
WO2024186890A1 (en) * | 2023-03-06 | 2024-09-12 | Intellia Therapeutics, Inc. | Compositions and methods for hepatitis b virus (hbv) genome editing |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100159585A1 (en) * | 2006-09-08 | 2010-06-24 | Ambrx, Inc. | Suppressor tRNA Transcription in Vertebrate Cells |
US20110105593A1 (en) * | 2006-10-11 | 2011-05-05 | Drexel University | MicroRNA-Formatted Multitarget Interfering RNA Vector Constructs and Methods of Using The Same |
US20140271550A1 (en) * | 2013-03-14 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses |
US20160317677A1 (en) * | 2013-12-12 | 2016-11-03 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
US20170049909A1 (en) * | 2014-02-18 | 2017-02-23 | Duke University | Compositions for the inactivation of virus replication and methods of making and using the same |
CN106520824A (en) * | 2016-09-30 | 2017-03-22 | 北京大北农科技集团股份有限公司 | Multi-target-point editing system and application thereof |
WO2017096237A1 (en) * | 2015-12-02 | 2017-06-08 | Ceres, Inc. | Methods for genetic modification of plants |
-
2018
- 2018-06-23 WO PCT/US2018/039179 patent/WO2018237369A2/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100159585A1 (en) * | 2006-09-08 | 2010-06-24 | Ambrx, Inc. | Suppressor tRNA Transcription in Vertebrate Cells |
US20110105593A1 (en) * | 2006-10-11 | 2011-05-05 | Drexel University | MicroRNA-Formatted Multitarget Interfering RNA Vector Constructs and Methods of Using The Same |
US20140271550A1 (en) * | 2013-03-14 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses |
US20160317677A1 (en) * | 2013-12-12 | 2016-11-03 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
US20170049909A1 (en) * | 2014-02-18 | 2017-02-23 | Duke University | Compositions for the inactivation of virus replication and methods of making and using the same |
WO2017096237A1 (en) * | 2015-12-02 | 2017-06-08 | Ceres, Inc. | Methods for genetic modification of plants |
CN106520824A (en) * | 2016-09-30 | 2017-03-22 | 北京大北农科技集团股份有限公司 | Multi-target-point editing system and application thereof |
Non-Patent Citations (3)
Title |
---|
AKITA ET AL.: "A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma", J CONTROL RELEASE, vol. 200, 24 December 2014 (2014-12-24), pages 97 - 105, XP029222024, ISSN: 0168-3659 * |
LU ET AL.: "Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants II: role of plasma esterases in drug release", AAPS JOUR, vol. 11, no. 1, March 2009 (2009-03-01), pages 120 - 122, XP035719004, DOI: doi:10.1208/s12248-009-9086-3 * |
WANG ET AL.: "The gRNA-miRNA-gRNA Ternary Cassette Combining CRISPR/Cas9 with RNAi Approach Strongly Inhibits Hepatitis B Virus Replication", THERANOSTICS, vol. 7, no. 12, 22 July 2017 (2017-07-22), pages 3090 - 3105, XP055482499, DOI: doi:10.7150/thno.18114 * |
Also Published As
Publication number | Publication date |
---|---|
WO2018237369A2 (en) | 2018-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018237369A3 (en) | Lipid nanoparticle (lnp)-mediated delivery of a crispr-expressing plasmid dna for treating chronic hepatitis b virus infection | |
PH12019500245A1 (en) | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | |
WO2017027350A3 (en) | Rnai therapy for hepatitis b virus infection | |
WO2015061294A3 (en) | Use of sting agonists to treat chronic hepatitis b virus infection | |
PH12016502102A1 (en) | Oligomers and oligomer conjugates | |
EP4306538A3 (en) | Peptide oligonucleotide conjugates | |
EP4385567A3 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
WO2017019891A3 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
WO2013039861A3 (en) | Engineered nucleic acids and methods of use thereof | |
WO2018183808A9 (en) | Antiviral therapeutic | |
JOP20210208A1 (en) | Rnai agents for hepatitis b virus infection | |
AR111908A1 (en) | THERAPEUTIC COMPOSITIONS AND METHODS OF TREATMENT OF HEPATITIS B | |
WO2020047161A3 (en) | Engineered immunostimulatory bacterial strains and uses thereof | |
MX2017011298A (en) | METHODS TO TREAT CANCER THAT HAS THE HEMICIGICAL LOSS OF TP53. | |
PH12017500010B1 (en) | Methods for the treatment of hepatitis b and hepatitis d virus infections | |
MX2022006846A (en) | Conjugates and methods for treating liver fibrosis. | |
WO2012016139A3 (en) | Sirna compositions and methods for treatment of hpv and other infections | |
PH12021552870A1 (en) | Compositions and methods for treating hepatitis b virus (hbv) infection | |
PH12018502320A1 (en) | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof | |
Hawkings et al. | RNAi-based strategy for Asian citrus psyllid (Diaphorina citri) control: a method to reduce the spread of citrus greening disease | |
Lin | Application of CRISPR-Cas System in the Treatment of Human Viral Disease | |
An et al. | Comparative Whole Genome Transcriptome Analysis of Rice Stripe Virus Viruliferous and Non Viruliferous Small Brown Planthopper, Laodelphax striatellus | |
Zhong | CRISPR-Cas System: A Feasible Solution for Getting Rid of Persistent Viral Infection | |
JO3769B1 (en) | RNAi Therapy for Hepatitis B Virus Infection | |
EA202192191A1 (en) | RNAi AGENTS AGAINST HEPATITIS B VIRUS INFECTION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18820145 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18820145 Country of ref document: EP Kind code of ref document: A2 |